Daytime Systolic Ambulatory Blood Pressure With a Two‐Step Switch From Candesartan to Olmesartan Monotherapy and the Fixed‐Dose Combination of Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL‐2). Issue 1 (8th November 2013)

• Record Type: Journal Article
• Authors: Bramlage, Peter; Zemmrich, Claudia; Gansz, Andrea; Sturm, Claus‐Dieter; Fimmers, Rolf; Nadal, Jennifer; Schmieder, Roland E.; Schrader, Joachim; Lüders, Stephan
• Is Part Of: Journal of clinical hypertension. Volume 16:Issue 1(2014:Jan.)
• Page Start: 41
• Page End: 46
• Publication Date: 2013-11-08
• Subjects: Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.12227
• Languages: English
• ISSNs: 1524-6175

Abstract

<abstract abstract-type="main" id="jch12227-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The objective of this study was to investigate the efficacy of the fixed‐dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg. This was a prospective, single‐arm, phase IV study. The primary endpoint was the change in mean daytime systolic blood pressure (BP). A total of 77 of 89 screened patients started candesartan 32 mg, 62 olmesartan 40 mg, and 57 olmesartan 40 mg/amlodipine 10 mg. Mean daytime systolic BP was reduced by 9.8±15.2 mm Hg (<italic>P</italic>&lt;.001) vs candesartan monotherapy. Office BP reduction was 9.2±18.8/5.0±8.9 mm Hg (<italic>P</italic>&lt;0.001). Treatment goals (&lt;140/90 mm Hg for office and &lt;135/85 mm Hg for ambulatory BP) were achieved in 58.2% and 78.4% of patients, respectively. There was one drug‐related adverse event (edema) and no serious adverse events. Patients of Caucasian ethnicity with moderate essential hypertension uncontrolled on candesartan experienced a further drop in BP using olmesartan and amlodipine.</p> </abstract>